Clinical trials: Pharmacokinetics of Enzalutamide
Healthy Subjects, Pharmacokinetics of MDV3100
A Study to Explore the Routes of Elimination of MDV3100
A study to investigate the excretion routes of radio-labelled MDV3100.
- Trial name
- NCT01911715
- Testing
- MDV3100
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Drug-Drug Interaction (DDI), Healthy Subjects
A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men
This study evaluates how a drug that alters liver enzymes (rifampin) affects the metabolism of enzalutamide in men by measuring concentrations of enzalutamide and its metabolites in plasma.
- Conditions
- Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics of Enzalutamide
- Trial name
- NCT02138799
- Testing
- enzalutamide, rifampin
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Subjects, Pharmacokinetics
Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole
A study to assess possible drug-drug interactions between MDV3100 and gemfibrozil and MDV3100 and Itraconazole.
- Conditions
- Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction
- Trial name
- NCT01913379
- Testing
- MDV3100, Gemfibrozil, Itraconazole
- Where
- France
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer
A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer
Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of testosterone in the body. One of the side effects of hormone therapy is hot flashes.
- Trial name
- NCT07783282
- Testing
- fezolinetant, enzalutamide, apalutamide
- Where
- Bulgaria
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Pharmacokinetics of MDV3100, Healthy Subjects
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group
This study will assess the influence of hepatic impairment on the pharmacokinetics, safety and tolerability of a single dose of MDV3100 in male subjects. The study will consist of two treatment arms.
- Conditions
- Pharmacokinetics of MDV3100, Healthy Subjects, Kidney Diseases
- Trial name
- NCT01901133
- Testing
- MDV3100
- Where
- Moldova
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Severe Hepatic Impairment, Normal Hepatic Function
A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men
The influence of severely diminished liver function on the metabolism, safety, and tolerability of a single oral dose of enzalutamide in a group of 8 men.
- Trial name
- NCT02138162
- Testing
- enzalutamide
- Where
- Bulgaria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.